RT Journal Article
SR Electronic
T1 Early plateau of SARS-CoV-2 seroprevalence identified by tripartite immunoassay in a large population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.31.20118554
DO 10.1101/2020.05.31.20118554
A1 Emmenegger, Marc
A1 De Cecco, Elena
A1 Lamparter, David
A1 Jacquat, Raphaël P. B.
A1 Ebner, Daniel
A1 Schneider, Mathias M.
A1 Morales, Itzel Condado
A1 Schneider, Dezirae
A1 Doğançay, Berre
A1 Guo, Jingjing
A1 Wiedmer, Anne
A1 Domange, Julie
A1 Imeri, Marigona
A1 Moos, Rita
A1 Zografou, Chryssa
A1 Trevisan, Chiara
A1 Gonzalez-Guerra, Andres
A1 Carrella, Alessandra
A1 Dubach, Irina L.
A1 Xu, Catherine K.
A1 Meisl, Georg
A1 Kosmoliaptsis, Vasilis
A1 Malinauskas, Tomas
A1 Burgess-Brown, Nicola
A1 Owens, Ray
A1 Hatch, Stephanie
A1 Mongkolsapaya, Juthathip
A1 Screaton, Gavin R.
A1 Schubert, Katharina
A1 Huck, John D.
A1 Liu, Feimei
A1 Pojer, Florence
A1 Lau, Kelvin
A1 Hacker, David
A1 Probst-Müller, Elsbeth
A1 Cervia, Carlo
A1 Nilsson, Jakob
A1 Boyman, Onur
A1 Saleh, Lanja
A1 Spanaus, Katharina
A1 von Eckardstein, Arnold
A1 Schaer, Dominik J.
A1 Ban, Nenad
A1 Tsai, Ching-Ju
A1 Marino, Jacopo
A1 Schertler, Gebhard F. X.
A1 Ebert, Nadine
A1 Thiel, Volker
A1 Gottschalk, Jochen
A1 Frey, Beat M.
A1 Reimann, Regina
A1 Hornemann, Simone
A1 Ring, Aaron M.
A1 Knowles, Tuomas P. J.
A1 Xenarios, Ioannis
A1 Stuart, David I.
A1 Aguzzi, Adriano
YR 2020
UL http://medrxiv.org/content/early/2020/06/22/2020.05.31.20118554.abstract
AB Serological assays can detect anti-SARS-CoV-2 (SARS2) antibodies, but their sensitivity often comes at the expense of specificity. Here we developed a Tripartite Automated Blood Immunoassay (TRABI) to assess the IgG response against SARS2. Calibration was performed with 90 prepandemic and 55 virologically and clinically confirmed COVID-19 samples. Posterior probabilities of seropositivities were calculated from 3×8 measurements of logarithmically diluted samples against the ectodomain and the receptor-binding domain of the spike protein and the nucleoprotein. We then performed 760’320 assays on 5’503 prepandemic and 26’177 copandemic samples from hospital patients and healthy blood donors. We found 176 seropositive samples between December 2019 and May 2020. The seroprevalence increased conspicuously in March 2020 but plateaued in late April at 0.8-1.6% in both cohorts, indicating an equilibrium between new infections and the waning of immunity. This points to a high effectiveness of containment measures and/or to unexpectedly rapid loss of humoral responses.Competing Interest StatementTPJK is a member of the board of directors of Fluidic Analytics. AA is a member of the board of directors of Mabylon AG which has funded antibody-related work in the Aguzzi lab in the past. All other authors declare no competing interests.Funding StatementInstitutional core funding by the University of Zurich and the University Hospital of Zurich to AA, as well as Driver Grant 2017DRI17 of the Swiss Personalized Health Initiative to AA. The robotic rig was acquired with a R'Equip grant of the Swiss National Foundation to AA. Screening methodolo-gies had been developed thank to the support of an Advanced Grant of the European Research Council and a Distinguished Scientist Award of the Nomis Foundation to AA. Funding by grants of Innovation Fund of the University Hospital Zurich to AA, AvE, DS, EPM, ME, and OB. Access to the Creoptix WAVE system was kindly provided by Creoptix AG. Waedenswil, CH. Utilization of the Fluidity One-W was kindly granted by Fluidic Analytics, Cambridge, UK. This work was supported by ETH Research Grant ETH-23 18-2 and a Ph.D. fellowship by Boehringer Ingelheim Fonds to KS. Raphael Jacquat acknowledges funding by the EPSRC for Doctoral Training in Sensor Technologies and Applications (grant EP/L015889/1). ICM acknowledges funding by the Swiss Gov-ernment FCS. Carlo Cervia was funded by a Swiss Academy of Medical Sciences fellowship (#323530-191220). GFXS was supported by an COVID-19 Emergency Fund of the Director of PSI. TM is supported by Cancer Research UK grants C20724/A14414 and C20724/A26752 to Christian Siebold (Oxford). Oxford work was supported by the MRC and Chinese Academy of Medical Sciences Innovation Fund for Medical Science, China Grant 2018-I2M-2-002. GRS is supported as a Wellcome Trust Senior Investigator (grant 095541/A/11/Z) and receives funding from the National Institute for Health Research Biomedical Research Centre Funding Scheme.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Kantonale Ethikkommission (KEK) ZuerichAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data underlying this study will be made available upon reasonable request. The biobank samples are limited and were exhausted in several instances. Therefore, while we will make ef-forts to provide microliter amounts of samples to other researchers, their availability is physically limited.